Clinical Trial Update: Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the mechanism of action of dimethyl fumarate in relapsing multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: WITHDRAWN